Abstract
Background: Physical inactivity and unhealthy dietary habits are known to be disadvantageous for the development of late adverse effects in survivors of childhood, adolescent, and young adult cancer. To make interventions, aimed at improving lifestyle, fit into the daily life of survivors, interventions should be designed and delivered in a person-centred way with a limited time burden. As part of the European PanCareFollowUp project, an eHealth intervention was developed to support sustainable changes to physical activity levels and/or diet of childhood, adolescent, and young adult cancer survivors. This feasibility study aims to gain insight into the feasibility and potential effect sizes of the PanCareFollowUp lifestyle intervention. Methods: The PanCareFollowUp lifestyle intervention consists of person-centred 3–6 screen-to-screen sessions with a certified lifestyle coach. The intervention will be evaluated with a single-arm pre-post feasibility study conducted at two survivorship care clinics in the Netherlands. A total of 60 participants who are (i) diagnosed with cancer <25 years, (ii) ≥ 5 years post-treatment, (iii) aged 16–55 years, and (iv) have a low physical activity level and/or unhealthy dietary intake manifested by overweight will be recruited. Using reports, hospital records, and questionnaires for survivors, coaches, and late effect doctors, feasibility will be based on (i) adherence to intervention, (ii) acceptability, (iii) practicality, (iv) integration/implementation, (v) demand, and (vi) attrition. The potential effect sizes of the intervention will be explored by determining the percentage of survivors that reach the personalized lifestyle goals that were set with the coach. Physical activity level, dietary intake, BMI, general self-efficacy, self-management, and motivation level will be assessed at three time points with questionnaires, reports, and/or an accelerometer. Discussion: Data of this study will be gathered to assess the feasibility and potential effect sizes. This will allow for further intervention refinement as needed as well as to inform a future large-scale intervention study and a manual for implementation at other centres. Trial registration: International Clinical Trial Registry Platform (ICTRP) number: NL8932 (ICTRP Search Portal (who.int)). Registered on September 29, 2020.
| Original language | English |
|---|---|
| Article number | 260 |
| Journal | Pilot and feasibility studies |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Dec 2022 |
Keywords
- Childhood, adolescent, and young adult cancer survivors
- Coaching
- Diet
- Feasibility
- Lifestyle
- Motivational interviewing
- Person-centred care
- Physical activity
- Screen-to-screen
- eHealth
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Pilot and feasibility studies, Vol. 8, No. 1, 260, 01.12.2022.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Person-centred online lifestyle coaching in childhood, adolescent, and young adult cancer survivors
T2 - protocol of the multicentre PanCareFollowUp lifestyle intervention feasibility study
AU - Bouwman, Eline
AU - Hermens, Rosella P. M. G.
AU - Brown, Morven C.
AU - Araújo-Soares, Vera
AU - Blijlevens, Nicole M. A.
AU - Kepak, Tomas
AU - Kepakova, Katerina
AU - Kremer, Leontien C. M.
AU - van den Oever, Selina R.
AU - van der Pal, Helena J. H.
AU - Skinner, Roderick
AU - Pluijm, Saskia M. F.
AU - Loonen, Jacqueline J.
AU - on behalf of the PanCareFollowUp Consortium
AU - Mulder, Renée L.
AU - van Kalsbeek, Rebecca J.
AU - Hjorth, Lars
AU - Follin, Cecilia
AU - Eriksson, Lill
AU - Relander, Thomas
AU - Engellau, Jacob
AU - Fjordén, Karin
AU - Bogefors, Karolina
AU - Holmqvist, Anna S.
AU - Haupt, Riccardo
AU - Muraca, Monica
AU - Nicolas, Brigitte
AU - Bagnasco, Francesca
AU - Benvenuto, Marina
AU - Aulicino, Anna
AU - Laudisi, Luca
AU - Hrstkova, Hana
AU - Bajciova, Viera
AU - Holikova, Marta
AU - Strublova, Lucie
AU - Uyttebroeck, Anne
AU - Renard, Marleen
AU - Jacobs, Sandra
AU - Segers, Heidi
AU - van Helvoirt, Monique
AU - Winther, Jeanette F.
AU - Mader, Luzius
AU - Frederiksen, Line E.
AU - Andersen, Elisabeth A. W.
AU - Michel, Gisela
AU - Boes, Stefan
AU - Roser, Katharina
AU - Göttgens, Irene
AU - Stollman, Iridi
AU - Penson, Adriaan
AU - Korevaar, Joke
N1 - Funding Information: The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824982. The funder had no role in the study design, data collection, data analysis, data interpretation, or writing the report. Funding Information: We thank all members of the PanCareFollowUp Consortium for their contribution in the project. The PanCareFollowUp Consortium, established in 2018, is a unique and multidisciplinary collaboration between 14 project partners from 10 European countries, including patient experts (https://pancarefollowup.eu). The aim of the consortium is to improve the quality of life for survivors of childhood, adolescent, and young adult (CAYA) cancer by bringing evidence-based, person-centred care to clinical practice. The PanCareFollowUp Consortium has developed and evaluated two interventions, including a person-centred and guideline-based model of survivorship care (care intervention) and an eHealth lifestyle coaching model (lifestyle intervention). After the project, replication manuals that contain the instructions and tools required for the implementation of the PanCareFollowUp interventions will be freely distributed. Members PanCareFollowUp Consortium Leontien C.M. Kremer, Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands; Department of Paediatrics, Emma Children's Hospital, Amsterdam UMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Faculty of Medicine, Utrecht University and Utrecht Medical Centre, Universiteitsweg 98, 3584 CG Utrecht, the Netherlands. Helena J.H. van der Pal, Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands; PanCare, Jacobus Bellamylaan 16, 1401 AZ Bussum, the Netherlands. Renée L. Mulder, Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands. Saskia M.F. Pluijm, Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands. Rebecca J. van Kalsbeek, Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands. Selina R. van den Oever, Princess Máxima Centre for Paediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, the Netherlands. Lars Hjorth, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Paediatrics, Lasarettsgatan 40, 221 85 Lund, Sweden. Cecilia Follin, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Oncology, Lasarettsgatan 40, 221 85 Lund, Sweden. Lill Eriksson, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Oncology, Lasarettsgatan 40, 221 85 Lund, Sweden. Thomas Relander, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Oncology, Lasarettsgatan 40, 221 85 Lund, Sweden. Jacob Engellau, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Oncology, Lasarettsgatan 40, 221 85 Lund, Sweden. Karin Fjordén, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Oncology, Lasarettsgatan 40, 221 85 Lund, Sweden. Karolina Bogefors, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Oncology, Lasarettsgatan 40, 221 85 Lund, Sweden. Anna S. Holmqvist, Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Paediatrics, Lasarettsgatan 40, 221 85 Lund, Sweden. Riccardo Haupt, Epidemiology and Biostatistics Unit and DOPO clinic, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147 Genoa, Italy. Monica Muraca, Epidemiology and Biostatistics Unit and DOPO clinic, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147 Genoa, Italy. Brigitte Nicolas, Epidemiology and Biostatistics Unit and DOPO clinic, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147 Genoa, Italy. Francesca Bagnasco, Epidemiology and Biostatistics Unit and DOPO clinic, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147 Genoa, Italy. Marina Benvenuto, Epidemiology and Biostatistics Unit and DOPO clinic, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147 Genoa, Italy. Anna Aulicino, Epidemiology and Biostatistics Unit and DOPO clinic, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5, 16147 Genoa, Italy. Luca Laudisi, Epidemiology and Biostatistics Unit and DOPO clinic, IRCCS Istituto Giannina Gaslini, Via G. Gaslini, 5–16147 Genoa, Italy. Vera Araujo-Soares, Department of Health Technology & Services Research, Technical Medical Centre, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands. Tomas Kepak, International Clinical Research Centre (FNUSA-ICRC) at St. Anne's University Hospital, Masaryk University, Pekařská 53, Brno 656 91, Czech Republic. Katerina Kepakova, International Clinical Research Centre (FNUSA-ICRC) at St. Anne's University Hospital, Masaryk University, Pekařská 53, Brno 656 91, Czech Republic. Hana Hrstkova, International Clinical Research Centre (FNUSA-ICRC) at St. Anne's University Hospital, Masaryk University, Pekařská 53, Brno 656 91, Czech Republic. Viera Bajciova, International Clinical Research Centre (FNUSA-ICRC) at St. Anne's University Hospital, Masaryk University, Pekařská 53, Brno 656 91, Czech Republic. Marta Holikova, International Clinical Research Centre (FNUSA-ICRC) at St. Anne's University Hospital, Masaryk University, Pekařská 53, Brno 656 91, Czech Republic. Lucie Strublova, International Clinical Research Centre (FNUSA-ICRC) at St. Anne's University Hospital, Masaryk University, Pekařská 53, Brno 656 91, Czech Republic. Anne Uyttebroeck, Department of Oncology, Paediatric Oncology, KU Leuven, Department of Paediatric Haematology and Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Marleen Renard, Department of Paediatric Haematology and Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Sandra Jacobs, Department of Oncology, Paediatric Oncology, KU Leuven, Department of Paediatric Haematology and Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Heidi Segers, Department of Oncology, Paediatric Oncology, KU Leuven, Department of Paediatric Haematology and Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Monique van Helvoirt, Department of Paediatric Haematology and Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Jeanette F. Winther, Childhood Cancer Research Group, Danish Cancer Society Research Centre, Strandboulevarden 49, 2100 Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University and Aarhus University Hospital, Palle Juul-Jensens Boulevard 82, 8200 Aarhus, Denmark. Luzius Mader, Childhood Cancer Research Group, Danish Cancer Society Research Centre, Strandboulevarden 49, 2100 Copenhagen, Denmark; Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland. Line E. Frederiksen, Childhood Cancer Research Group, Danish Cancer Society Research Centre, Strandboulevarden 49, 2100 Copenhagen, Denmark. Elisabeth A. W. Andersen, Statistics and Data Analysis, Danish Cancer Society Research Centre, Strandboulevarden 49, 2100 Copenhagen, Denmark. Gisela Michel, University of Lucerne, Department of Health Sciences and Medicine, Frohburgstrasse 3, P.O. Box 4466, 6002 Lucerne, Switzerland. Stefan Boes, University of Lucerne, Department of Health Sciences and Medicine, Frohburgstrasse 3, P.O. Box 4466, 6002 Lucerne, Switzerland. Katharina Roser, University of Lucerne, Department of Health Sciences and Medicine, Frohburgstrasse 3, P.O. Box 4466, 6002 Lucerne, Switzerland. Jacqueline Loonen, Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Hematology, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. Rosella Hermens, Radboud University Medical Centre, Radboud Institute for Health Sciences, Scientific Institute for Quality of Healthcare (IQ Healthcare), Geert Grooteplein 21, 6525 EZ, Nijmegen, the Netherlands. Irene Göttgens, Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Primary and Community Care, Geert Grooteplein 21, 6525 EZ, Nijmegen, the Netherlands. Eline Bouwman, Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Hematology, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. Iridi Stollman, Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Hematology, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. Adriaan Penson, Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Hematology, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. Dionne Breij, Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Hematology, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands. Roderick Skinner, Newcastle University Centre for Cancer, Wolfson Childhood Cancer Research Centre, Herschel Building, Brewery Lane, Newcastle upon Tyne, NE1 7RU, United Kingdom; Great North Children's Hospital, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4 LP, United Kingdom; Translational and Clinical Research Institute, Wolfson Childhood Cancer Research Centre, Herschel Building, Brewery Lane, Newcastle upon Tyne, NE1 7RU, United Kingdom. Morven C. Brown, Population Health Sciences Institute, Newcastle University, Sir James Spence Institute, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, United Kingdom; Newcastle University Centre for Cancer, Wolfson Childhood Cancer Research Centre, Herschel Building, Brewery Lane, Newcastle upon Tyne, NE1 7RU, United Kingdom. Vera Araujo-Soares, Department of Health Technology & Services Research, Technical Medical Centre, University of Twente, P.O. Box 217, 7500 AE Enschede, the Netherlands Samira Essiaf, European Society for Paediatric Oncology, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30, BE-1200 Brussels, Belgium. Anne Blondeel, European Society for Paediatric Oncology, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30, BE-1200 Brussels, Belgium. William Sciberras, European Society for Paediatric Oncology, c/o BLSI, Clos Chapelle-aux-Champs 30, Bte 1.30.30, BE-1200 Brussels, Belgium. Joke Korevaar, Netherlands Institute for Health Services Research (Nivel), P.O. Box 1568, 3500 BN Utrecht, the Netherlands. Mieke Rijken, Netherlands Institute for Health Services Research (Nivel), P.O. Box 1568, 3500 BN Utrecht, the Netherlands; University of Eastern Finland, Department of Health and Social Management, P.O. Box 1627, FI-70211 Kuopio, Finland. Anita Kienesberger, Childhood Cancer International Europe, Servitengasse 5/16, 1090 Vienna, Austria. Jaap den Hartogh, Childhood Cancer International Europe, Servitengasse 5/16, 1090 Vienna, Austria. Hannah Gsell, Childhood Cancer International Europe, Servitengasse 5/16, 1090 Vienna, Austria. Carina Schneider, Childhood Cancer International Europe, Servitengasse 5/16, 1090 Vienna, Austria. Jaap den Hartogh, Childhood Cancer International Europe, Servitengasse 5/16, 1090 Vienna, Austria. Edit Bardi, PanCare, Jacobus Bellamylaan 16, 1401 AZ Bussum, the Netherlands. Jeroen te Dorsthorst, PanCare, Jacobus Bellamylaan 16, 1401 AZ Bussum, the Netherlands. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out. Publisher Copyright: © 2022, The Author(s).
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Background: Physical inactivity and unhealthy dietary habits are known to be disadvantageous for the development of late adverse effects in survivors of childhood, adolescent, and young adult cancer. To make interventions, aimed at improving lifestyle, fit into the daily life of survivors, interventions should be designed and delivered in a person-centred way with a limited time burden. As part of the European PanCareFollowUp project, an eHealth intervention was developed to support sustainable changes to physical activity levels and/or diet of childhood, adolescent, and young adult cancer survivors. This feasibility study aims to gain insight into the feasibility and potential effect sizes of the PanCareFollowUp lifestyle intervention. Methods: The PanCareFollowUp lifestyle intervention consists of person-centred 3–6 screen-to-screen sessions with a certified lifestyle coach. The intervention will be evaluated with a single-arm pre-post feasibility study conducted at two survivorship care clinics in the Netherlands. A total of 60 participants who are (i) diagnosed with cancer <25 years, (ii) ≥ 5 years post-treatment, (iii) aged 16–55 years, and (iv) have a low physical activity level and/or unhealthy dietary intake manifested by overweight will be recruited. Using reports, hospital records, and questionnaires for survivors, coaches, and late effect doctors, feasibility will be based on (i) adherence to intervention, (ii) acceptability, (iii) practicality, (iv) integration/implementation, (v) demand, and (vi) attrition. The potential effect sizes of the intervention will be explored by determining the percentage of survivors that reach the personalized lifestyle goals that were set with the coach. Physical activity level, dietary intake, BMI, general self-efficacy, self-management, and motivation level will be assessed at three time points with questionnaires, reports, and/or an accelerometer. Discussion: Data of this study will be gathered to assess the feasibility and potential effect sizes. This will allow for further intervention refinement as needed as well as to inform a future large-scale intervention study and a manual for implementation at other centres. Trial registration: International Clinical Trial Registry Platform (ICTRP) number: NL8932 (ICTRP Search Portal (who.int)). Registered on September 29, 2020.
AB - Background: Physical inactivity and unhealthy dietary habits are known to be disadvantageous for the development of late adverse effects in survivors of childhood, adolescent, and young adult cancer. To make interventions, aimed at improving lifestyle, fit into the daily life of survivors, interventions should be designed and delivered in a person-centred way with a limited time burden. As part of the European PanCareFollowUp project, an eHealth intervention was developed to support sustainable changes to physical activity levels and/or diet of childhood, adolescent, and young adult cancer survivors. This feasibility study aims to gain insight into the feasibility and potential effect sizes of the PanCareFollowUp lifestyle intervention. Methods: The PanCareFollowUp lifestyle intervention consists of person-centred 3–6 screen-to-screen sessions with a certified lifestyle coach. The intervention will be evaluated with a single-arm pre-post feasibility study conducted at two survivorship care clinics in the Netherlands. A total of 60 participants who are (i) diagnosed with cancer <25 years, (ii) ≥ 5 years post-treatment, (iii) aged 16–55 years, and (iv) have a low physical activity level and/or unhealthy dietary intake manifested by overweight will be recruited. Using reports, hospital records, and questionnaires for survivors, coaches, and late effect doctors, feasibility will be based on (i) adherence to intervention, (ii) acceptability, (iii) practicality, (iv) integration/implementation, (v) demand, and (vi) attrition. The potential effect sizes of the intervention will be explored by determining the percentage of survivors that reach the personalized lifestyle goals that were set with the coach. Physical activity level, dietary intake, BMI, general self-efficacy, self-management, and motivation level will be assessed at three time points with questionnaires, reports, and/or an accelerometer. Discussion: Data of this study will be gathered to assess the feasibility and potential effect sizes. This will allow for further intervention refinement as needed as well as to inform a future large-scale intervention study and a manual for implementation at other centres. Trial registration: International Clinical Trial Registry Platform (ICTRP) number: NL8932 (ICTRP Search Portal (who.int)). Registered on September 29, 2020.
KW - Childhood, adolescent, and young adult cancer survivors
KW - Coaching
KW - Diet
KW - Feasibility
KW - Lifestyle
KW - Motivational interviewing
KW - Person-centred care
KW - Physical activity
KW - Screen-to-screen
KW - eHealth
UR - http://www.scopus.com/inward/record.url?scp=85144169417&partnerID=8YFLogxK
U2 - https://doi.org/10.1186/s40814-022-01221-x
DO - https://doi.org/10.1186/s40814-022-01221-x
M3 - Article
C2 - 36527164
SN - 2055-5784
VL - 8
JO - Pilot and feasibility studies
JF - Pilot and feasibility studies
IS - 1
M1 - 260
ER -